• Home
  • News
  • Analysis
  •  
    Regions
    • Australasia
    • Southeast Asia
    • Greater China
    • North Asia
    • South Asia
    • North America
    • Europe
    • Central Asia
    • MENA
  •  
    Funds
    • LPs
    • Buyout
    • Growth
    • Venture
    • Renminbi
    • Secondary
    • Credit/Special Situations
    • Infrastructure
    • Real Estate
  •  
    Investments
    • Buyout
    • Growth
    • Early stage
    • PIPE
    • Credit
  •  
    Exits
    • IPO
    • Open market
    • Trade sale
    • Buyback
  •  
    Sectors
    • Consumer
    • Financials
    • Healthcare
    • Industrials
    • Infrastructure
    • Media
    • Technology
    • Real Estate
  • Events
  • Chinese edition
  • Data & Research
  • Weekly Digest
  • Newsletters
  • Sign in
  • Events
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)870 240 8859

      Email: customerservices@incisivemedia.com

      • Sign in
     
      • Saved articles
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • RSS
    • Twitter
    • LinkedIn
    • Newsletters
  • Free Trial
  • Subscribe
  • Weekly Digest
  • Chinese edition
  • Data & Research
    • Latest Data & Research
      2023-china-216x305
      Regional Reports

      The reports review the year's local private equity and venture capital activity and are filled with up-to-date data and intelligence on fundraising, investments, exits and M&A. The regional reports also feature information on key companies.

      Read more
      2016-pevc-cover
      Industry Review

      Asian Private Equity and Venture Capital Review provides an independent overview of the private equity, venture capital and M&A activities in the Asia region. It delivers insights on investments made, capital raised, sector specific figures and more.

      Read more
      AVCJ Database

      AVCJ Database is the ultimate link between Asian dealmakers and those who provide advisory, financial, legal and technological services to the private equity, venture capital and M&A industries. It is packed with facts and figures on more than 153,000 companies and almost 117,000 transactions.

      Read more
AVCJ
AVCJ
  • Home
  • News
  • Analysis
  • Regions
  • Funds
  • Investments
  • Exits
  • Sectors
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)870 240 8859

    Email: customerservices@incisivemedia.com

    • Sign in
 
    • Saved articles
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 

Healthcare

Zhiyun raises $144m for chronic disease management platform

Zhiyun Health, a Chinese online healthcare services provider, has raised more than RMB1 billion ($144 million) across two rounds. It describes the investment as the largest private funding event globally in the chronic disease management space.

  • Greater China
  • 10 January 2020
China's Transcenta secures $100m funding round

Transcenta Holding, a Chinese biotech company formed last year through the merger of MabSpace Bioscience and Hangzhou Just Biotherapeutics (HJB), has raised $100 million in an extended Series B funding round.

  • Greater China
  • 10 January 2020
Chinese drug developer wins General Atlantic backing

General Atlantic has led a $69 million Series D round of funding for Adagene, a Chinese drug developer with one cancer treatment currently in phase one clinical trials in China and the US.

  • Greater China
  • 09 January 2020
mahkota-medical-centre
EQT backs Southeast Asia hospital operator

EQT Partners has confirmed an investment of undisclosed size in Health Management International (HMI), a hospital operator with a presence in Singapore, Malaysia, and Indonesia.

  • Southeast Asia
  • 08 January 2020
China’s CF PharmTech raises $90m Series E

CF PharmTech, a Chinese devices maker focused on respiratory health, has raised $90 million in Series E funding led by local private equity investor New Alliance Capital.

  • Greater China
  • 08 January 2020
Everstone backs US, India-based generics developer

The Everstone Group has agreed to invest $50 million in Slayback Pharma, a developer of generic and specialty drugs with a presence in India and the US.

  • South Asia
  • 07 January 2020
India's True North makes $75m biosimilars bet

True North has invested INR5.36 billion ($74.6 million) in the biosimilars business of India-listed pharmaceuticals giant Biocon.

  • South Asia
  • 07 January 2020
Chinese genetic testing player secures $115m round

Geneseeq, a Chinese genetic testing company that focuses on treatments for cancer, has raised RMB800 million ($115 million) in a funding round led by state-owned China Reform Holding Corporation.

  • Greater China
  • 02 January 2020
Chinese biopharma player secures $100m Series B

Elpiscience, a Shanghai-based biopharmaceutical company has completed a $100 million Series B round of funding led by specialist healthcare GP Hyfinity Investments.

  • Greater China
  • 31 December 2019
awak
Singapore medical tech start-up raises $40 million

Awak Technologies, a Singaporean start-up that makes wearable dialysis treatment devices, has raised $40 million co-led by Vickers Venture Partners and an unnamed medical technology company.

  • Southeast Asia
  • 17 December 2019
China's KeChow Pharma gets $45m Series C

Shanghai Kechow Pharma, a Chinese small molecule targeted drug developer, has raised a $45 million Series C round led by Decheng Capital.

  • Greater China
  • 16 December 2019
General Atlantic promotes China healthcare head

Lefei Sun, who helped establish and now leads General Atlantic’s healthcare and life sciences business in China, has been promoted to managing director.

  • Greater China
  • 12 December 2019
pharmacy
Deal focus: EQT fulfills Laobaixing's prescription

EQT spent 11 years helping Chinese pharmacy chain Laobaixing evolve from large-format laggard into a focused and efficient operator that meets the needs of modern customers. It has now exited with a 7.7x return

  • Greater China
  • 11 December 2019
Local GPs commit $71m to China biotech player

EOC Pharma, a Chinese biotech developer focused on cancer treatments, has closed a RMB500 million ($71 million) Series C round raised from a group of local private equity investors.

  • Greater China
  • 04 December 2019
Chinese biopharma start-up raises $43m Series B

Chinese cancer and autoimmune disease therapy developer Clover Biopharmaceuticals has raised a $43 million Series B round led by local VC Lapam Capital and US private equity firm Delos Capital.

  • Greater China
  • 02 December 2019
China’s Loyal Valley closes second US dollar fund at $465m

China’s Loyal Valley Capital has closed its second US dollar-denominated fund at $465 million. The target was $400 million with a hard cap of $440 million.

  • Greater China
  • 02 December 2019
FountainVest, Primavera invest $557m in China pharmacy chain

FountainVest Partners and Primavera Capital have paid $557 million for a 24.78% stake in Chinese pharmacy chain Laobaixing. It will provide a full exit for EQT Partners.

  • Greater China
  • 29 November 2019
teeth-smile
Singapore dental products start-up receives $13m Series A

Zenyum, a Singapore-based manufacturer of 3D-printed cosmetic dental products, has raised $13.6 million in Series A funding from RTP Global, Sequoia Capital India, TNB Aura, and Seeds Capital.

  • Southeast Asia
  • 28 November 2019
Japan health tech player SmartScan gets $10m Series A

SmartScan, a Japanese medical technology supplier focused on software for diagnostics equipment, has raised a JPY1.3 billion ($10.3 million) Series A round from domestic VCs.

  • North Asia
  • 28 November 2019
China’s Genetron secures $50m Series D, seeks US IPO

Genetron Holdings, a precision oncology technology developer in China, has raised a $50 million Series D round and filed for a US IPO.

  • Greater China
  • 25 November 2019
Chinese cancer database provider secures $140m

Medbanks, a Chinese oncology database platform, has raised around RMB1 billion ($140 million) in an extended Series D funding round led by Tencent Holdings and Wu Capital.

  • Greater China
  • 25 November 2019
blood-test
IHH leads $20m round for Singapore science ministry spin-out

Lucence, a cancer screening start-up that spun out from Singapore’s Agency for Science, Technology and Research in 2016, has raised $20 million in Series A funding.

  • Southeast Asia
  • 21 November 2019
Baring Asia to buy Lumenis from XIO for $1b

Baring Private Equity Asia has agreed to buy Lumenis, an Israel-headquartered medical devices manufacturer that counts Asia as its largest market, from XIO Group for a valuation of $1 billion.

  • MENA
  • 21 November 2019
New Frontier Group: Another kind of platform

Led by two former executives with The Blackstone Group in Asia, New Frontier Group has so far looked beyond traditional PE funding channels as it builds large-scale Chinese healthcare platforms

  • Greater China
  • 21 November 2019
31 32 33
  • About AVCJ
  • Advertise
  • Contacts
  • About ION Analytics
  • Terms of use
  • Privacy policy
  • Group disclaimer
  • RSS
  • Twitter
  • LinkedIn
  • Newsletters

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013